H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

Immune Targeting Systems, specializing in the development of novel T cell immune therapies, has been developing an exciting new T cell vaccine (FlunisynTM) designed to protect humans from all strains of seasonal and pandemic influenza A.

18 Aug 2014

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014.

23 Jul 2014

Johns Hopkins researchers awarded NIH contract to launch new center to track influenza viruses

The National Institutes of Health has awarded a contract to researchers at The Johns Hopkins University to launch a new center devoted to developing innovative ways to identify and track influenza viruses worldwide.

6 May 2014

Nanoviricides develops new drug candidates against MERS infection

...

6 May 2014

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries.

28 Apr 2014

Pediatrician reviews co-pathogenesis of influenza viruses with bacteria in lung

Le Bonheur Children's Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited to submit a review in the April issue of Nature Reviews Microbiology, one of the world's foremost scientific publications.

22 Apr 2014

Study finds ginseng can help prevent, treat influenza and RSV infection

Ginseng can help treat and prevent influenza and respiratory syncytial virus (RSV), a respiratory virus that infects the lungs and breathing passages, according to research findings by a scientist in Georgia State University's new Institute for Biomedical Sciences.

22 Apr 2014

UTMB experts honored with Lifetime Achievement Award for contributions to study of deadly diseases

The global experts who study the deadliest infectious diseases recognized the contributions of Frederick A. Murphy and Thomas G. Ksiazek, professors at the University of Texas Medical Branch, with a Lifetime Achievement Award at the 6th annual International Symposium on Filoviruses. The filoviruses include Ebola and Marburg viruses that cause death in 50 to 90 percent of people infected. The current outbreak of Ebola virus raging in West Africa has caused more than 100 deaths so far.

16 Apr 2014

Findings pave way for potential therapy to combat H1N1 flu virus

Flu epidemics cause up to half a million deaths worldwide each year, and emerging strains continually threaten to spread to humans and cause even deadlier pandemics. A study by McGill University professor Maziar Divangahi published by Cell Press on April 10 in the journal Immunity reveals that a drug that inhibits a molecule called prostaglandin E2 (PGE2) increases survival rates in mice infected with a lethal dose of the H1N1 flu virus.

11 Apr 2014

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza.

11 Apr 2014

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains.

8 Apr 2014

EPFL scientists develop computer tool to identify mutations that make influenza resistant to Tamiflu

Tamiflu is one of the few available treatments for those who come down with the flu. But the virus quickly develops resistance; multiplying at a rate of several generations a day, these tiny pathogens rapidly accumulate genetic mutations. Because of this, they have a good chance of developing counterattacks to the antiviral. How can these infinitesimal variations be identified within the immensity of the virus' genetic code? EPFL researchers have created a computer tool that can shed light on the flu virus' formidable adaptability.

1 Apr 2014

Tamiflu cuts H1N1 pandemic deaths by 25%, shows study

Adults hospitalised with H1N1 influenza during the 2009–2010 pandemic were 25% less likely to die from the disease if they were given antiviral drugs called neuraminidase inhibitors (NAIs) such as Tamiflu, according to a large meta-analysis involving more than 29 000 patients from 38 countries, published in The Lancet Respiratory Medicine journal. The findings also indicate that treatment within 2 days of flu symptoms developing halved the risk of death compared with later treatment or no treatment.

20 Mar 2014

H1N1 News and Research

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Johns Hopkins researchers awarded NIH contract to launch new center to track influenza viruses

Nanoviricides develops new drug candidates against MERS infection

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Pediatrician reviews co-pathogenesis of influenza viruses with bacteria in lung

Study finds ginseng can help prevent, treat influenza and RSV infection

UTMB experts honored with Lifetime Achievement Award for contributions to study of deadly diseases

Findings pave way for potential therapy to combat H1N1 flu virus

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

EPFL scientists develop computer tool to identify mutations that make influenza resistant to Tamiflu

Tamiflu cuts H1N1 pandemic deaths by 25%, shows study

Study shows only 23% of seasonal and pandemic flu caused symptoms

Scientists map key elements of immune overreaction triggered by influenza virus infection

TSRI scientists describe severe immune overreaction caused by flu infections

CDC report reveals that younger age group is mostly hit by flu this season

Upstream interventions may provide options to contain emerging pathogens at source

Study provides comprehensive analysis of the evolutionary relationships of influenza virus

Unvaccinated flu patients need more intensive care

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News